Lightnews — Scholar-powered news

Priya Garg

@priyagargiddoc.bsky.social

1.1K followers 410 following 37 posts

Infectious Diseases Physician. Clinician Researcher. Immunocompromised Host ID. Transplant ID. @pmcc @ncic @wslhd Music lover, keen photographer and proud girl mum. #MedSky #TxID #WomeninSTEM #IDSky #InfectionPrevention #IDOnc

Posts Media Videos Starter Packs

Pinned

Priya Garg @priyagargiddoc.bsky.social · Nov 13

Delighted to be early to the party (for once)! #IDSky #MedSky
ID Physician and clinician researcher in Melbourne, interested in Transplant-ID, Immunocompromised Host, Tropical Med & Infection Prevention. Excited to join the @bsky.app ID community 💪

2 2 40

Priya Garg @priyagargiddoc.bsky.social · 17d

I think this is a watch this space.. !

Reposted by Priya Garg

The Medical Journal of Australia @mja.com.au · Feb 5

🔔 NEW in the Medical Journal of Australia

Prolonged SARS‐CoV‐2 shedding in a lung transplant recipient: time for flexibility in infection prevention?

✍️ Alyssa Pradhan, David Pham, Alexander Brennan, Jen Kok and Priya Garg

OPEN ACCESS https://buff.ly/42yLhDb

2 2

Reposted by Priya Garg

NCICancer @ncicancer.bsky.social · Sep 5

Australia’s first multi-site study of infections in cancer & transplant patients, PROSPER, is now published in BMJ Open! It will guide future infection prevention & control for this vulnerable group.

Read the full article here: bmjopen.bmj.com/content/15/7...

1 1

Reposted by Priya Garg

Michelle Yong @michyong.bsky.social · Sep 1

🔥🔥Just published in #CID world-first clinical trial of IFN-a nasal spray vs placebo reduced #COVID 🦠 incidence 📉 by 40% in cancer pts. Well tolerated, safe, effective…

Full link here: academic.oup.com/cid/advance-ar…

1 3 17

Priya Garg @priyagargiddoc.bsky.social · Aug 28

Always exciting to learn more about novel cellular therapies for IFIs at Westmead Hospital ID week! (And see all the research across the precinct) @westmeadinst.bsky.social #TxID

2 3

Priya Garg @priyagargiddoc.bsky.social · Aug 13

Thanks Catherine! ☺️

Priya Garg @priyagargiddoc.bsky.social · Aug 12

Pleased to publish the INTERACT study - describing current infection prevention & surveillance practice in the care of Australasian cancer/transplant patients & areas for future research (& thankful to all who participated) 🌟 @ncicancer.bsky.social #TxID #IDSky

www.ajicjournal.org/article/S019...

The INTERACT study: Infection prevention and surveillance practice in the care of the Australasian cancer and transplant population

Australasian cancer and transplant populations are expanding, with increased infection risk related to prolonged survivorship and broader use of novel immunosuppressants. To optimise care, standardise...

www.ajicjournal.org

4 5 13

Reposted by Priya Garg

Chelsea Gorsline, MD 🦠🍄 @chelseagorsline.bsky.social · Nov 25

Our new @txidfellows.bsky.social paper is out! This one on ASP in #TxID. Practical tips for beginners and early career faculty. @courtharrismd.bsky.social @rebeccakumar.bsky.social @divsharma.bsky.social @mirandapharmdmph.bsky.social @hannah-imlay.bsky.social

Antibiotic Steward 🅱️C🆔🅿️🌟 @absteward.bsky.social · Nov 25

🆕️🔥Article @thetxidjournal.bsky.social
Not Just an Oxymoron: The Utilitarian's Guide to Antimicrobial Stewardship in Transplant Infectious Diseases
Table ✨️2: TID ASP opportunities & initiatives
#idsky #medsky #Txid
onlinelibrary.wiley.com/doi/full/10....

3 12 34

Priya Garg @priyagargiddoc.bsky.social · Aug 8

The ECIL guidelines are gold!

Reposted by Priya Garg

Ben Teh @benwteh.bsky.social · Aug 8

Delighted to have been part of these important ECiL-10 c diff guidelines specific to our haematology patients.
#TxID @ncicancer.bsky.social @ichs-global.bsky.social @theebmt.bsky.social

www.sciencedirect.com/science/arti...

ScienceDirect.com | Science, health and medical journals, full text articles and books.

smex-ctp.trendmicro.com

1 1 2

Priya Garg @priyagargiddoc.bsky.social · Aug 5

What a great bunch! 👋🏽

Reposted by Priya Garg

TransplantID.Net - American Society of Transplantation @transplantidnet.bsky.social · Jul 1

[email protected] has #ID #HSCT #CAR-T guidelines in TCT Journal
transplantid.net "GUIDELINES"▶️ "ASTCT Guidelines"📁

#️⃣ 9️⃣ : Mgmt of HHV-6B after HSCT and CAR-T
Bonus: Tests for chromosomal integration!
Thanks Aneela Majeed @clevelandclinic.bsky.social!

transplantid.net/37V7X3QT

1 1

Priya Garg @priyagargiddoc.bsky.social · Aug 1

Excited to see what the PROSPER study (point prevalence of infections in cancer & transplant) demonstrates.. @ncicancer.bsky.social 🦠 @bmj.com #TxID #IDSky #EpiSky

Estimating the prevalence of key healthcare-associated and opportunistic infections in Australian transplant and cancer populations: protocol for the PROSPER point prevalence study

Introduction The immunocompromised host (ICH) is at increased risk for a range of opportunistic and healthcare-associated infections (OI/HAIs). With increased use of novel therapeutics and prolonged s...

bmjopen.bmj.com

Reposted by Priya Garg

NCICancer @ncicancer.bsky.social · Jun 27

We were proud to be well represented at the inaugural The
Transplantation Society of Australia and New Zealand Infectious Disease Day on 20 June 2025 — a fantastic event co-badged with ASID Immunocompromised Host Special Interest Group.

1 3

Priya Garg @priyagargiddoc.bsky.social · Jun 23

Thanks so much for sharing @bradgardiner.bsky.social

Priya Garg @priyagargiddoc.bsky.social · Jun 22

Pleased to present our subgroup analysis @TSANZ. Would IPC specific to the SOT cohort be valuable? Which HAIs/OIs should we monitor, and how do we build a national framework for success? @ncicancer.bsky.social #TxID #IDSky

1 2 10

Priya Garg @priyagargiddoc.bsky.social · Jun 21

Extremely cold! Even for an ex-Brit 🤣

Priya Garg @priyagargiddoc.bsky.social · Jun 21

#TxID #IDSky

Priya Garg @priyagargiddoc.bsky.social · Jun 20

Always a pleasure to hear @aussiedocwolfe.bsky.social speak on advances in organ transplantation & thankful to chair a session on infection surveillance in transplant @TSANZ Transplant Infectious Disease day! Congrats to the committee for putting together an exciting inaugural meeting.

2 5

Reposted by Priya Garg

Violet Zhu @vzhu1.bsky.social · May 21

Happy Infectious Diseases Pharmacists Day to my colleagues, mentors, and clinician-researcher heroes #IDPharmacistsDay #SIDPAdvocacy @adphaau.bsky.social @sidpharm.bsky.social @ncicancer.bsky.social

2 6 24

Priya Garg @priyagargiddoc.bsky.social · May 22

We would be lost without you! 💊

Priya Garg @priyagargiddoc.bsky.social · May 15

#TxID #IDSky #IDOnc 🙌🏽

Priya Garg @priyagargiddoc.bsky.social · May 15

Grateful to have received a travel stipend to spend an exciting few days at the @fredhutch.bsky.social ICH Symposium in Seattle, present & learn from experts in the field- Including @kottonnelson.bsky.social, Jay Fishman & our own @ncicancer.bsky.social @michyong.bsky.social, Monica Slavin & more..!

1 2 11

Reposted by Priya Garg

Ilan Schwartz @germhuntermd.bsky.social · May 9

Herpes Simplex Virus and Drug Resistance - Comprehensive Update on Resistance Mutations and Implications for Clinical Management: A Narrative Review

Open Access @cmijournal.bsky.social

www.clinicalmicrobiologyandinfection.com/article/S119... #IDSky #TxID

Figure 1 Overview of mechanisms of action of different drugs used in the treatment of infection with HSV-1/2. The nucleoside analogues ACV, PCV and BVDU are phosphorylated by viral TK. ACV-P, PCV-P, BVDU-P and CDV are biphosphorylated by cellular kinases. The phosphorylated compounds are then incorporated into nascent DNA. This leads to a stop in viral replication or, in case of BVDU, destabilizes the DNA and inhibits the replication. FOS inhibits replication by directly binding POL and inhibiting the pyrophosphate binding site competitively. AMNV and PTV bind to the viral helicase-primase complex. This inhibits DNA unwinding and therefore inhibits replication. ACV: aciclovir; PCV: penciclovir; BVDU: brivudine; CDV: cidofovir; FOS: foscarnet; AMNV: amenamevir; PTV: pritelivir.

1 9 20

Reposted by Priya Garg

Ilan Schwartz @germhuntermd.bsky.social · Apr 26

Cryptococcal Meningitis Treatment Beyond HIV: Recognizing the need for Individualized Immune-Based Strategies

Hyunah Yoon, Liise-anne Pirofsky, @drboulware.bsky.social

In non-HIV-associated CM, ⬇️ing immunosuppression --> ⬆️ inflammation --> 🧠 damage.

academic.oup.com/cid/advance-... #TxID #IDSky

A line graph illustrating immunosuppressive drug intensity and immune cell recovery (CD4+ T, B and NK cells) over months following kidney transplantation, highlighting a window of heightened cryptococcal disease risk.

Two parabola diagrams comparing HIV-associated cryptococcal damage and non-HIV transplant-associated damage. In both settings, too little or too much immune response can result in host damage (left and right arms of the parabola). However, in non-HIV transplant patients, the overall position on the parabola is less predictable, due to the heterogeneous effects of immunosuppressive medications before and during cryptococcal infection.

1 10 21